DOCSLIB.ORG

Autoimmune Related Pancreatitis Gut: First Published As 10.1136/Gut.51.1.1 on 1 July 2002

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Autoimmune Related Pancreatitis Gut: First Published As 10.1136/Gut.51.1.1 on 1 July 2002 1 LEADING ARTICLE Autoimmune related pancreatitis Gut: first published as 10.1136/gut.51.1.1 on 1 July 2002. Downloaded from K Okazaki, T Chiba ............................................................................................................................. Gut 2002;51:1–4 Since the first documented case of a particular form of (i) increased levels of serum gammaglobulin or pancreatitis with hypergammaglobulinaemia, similar IgG; cases have been reported, leading to the concept of an (ii) presence of autoantibodies; autoimmune related pancreatitis or so-called (iii) diffuse enlargement of the pancreas; “autoimmune pancreatitis”. Although it has not yet been (iv) diffusely irregular narrowing of the main pancreatic duct and occasionally stenosis of the widely accepted as a new clinical entity, the present intrapancreatic bile duct on endoscopic retro- article discusses the recent concept of autoimmune grade cholangiopancreatographic (ERCP) im- pancreatitis. ages; .......................................................................... (v) fibrotic changes with lymphocyte infiltration; (vi) no symptoms or only mild symptoms, usually SUMMARY without acute attacks of pancreatitis; Since Sarles et al reported a case of particular (vii) rare pancreatic calcification or cysts; pancreatitis with hypergammaglobulinaemia, (viii) occasional association with other auto- similar cases have been noted, which has led to immune diseases; and the concept of an autoimmune related pancreati- tis or so-called “autoimmune pancreatitis”. The (ix) effective steroid therapy. clinical characteristics are: (i) increased levels of Other nomenclatures such as “chronic inflam- serum gammaglobulin or IgG; (ii) presence of matory sclerosis of the pancreas”,1 “sclerosing autoantibodies; (iii) diffuse enlargement of the pancreatitis”,15 “pancreatitis showing the narrow- pancreas; (iv) diffusely irregular narrowing im- ing appearance of the pancreatic duct (PNPD)”,16 ages of the main pancreatic duct; (v) fibrotic and “sclerosing pancreatocholangitis”14 have also http://gut.bmj.com/ changes with lymphocyte infiltration; (vi) no or been proposed. However, cases without evidence only mild symptoms; (vii) rare pancreatic calcifi- of autoimmunity should be classified as a cation or pancreatic cysts; (viii) occasional associ- different entity from AIP,even if steroid therapy is ation with other autoimmune diseases; and (ix) effective. effective steroid therapy. In addition to various systemic autoimmune diseases, diabetes mellitus Primary and secondary AIP or bile duct lesions responsive to steroid therapy Recently, cases of primary (or isolated) AIP with- are often observed. Further studies are needed to on September 26, 2021 by guest. Protected copyright. out other autoimmune diseases have been re- clarify the pathogenesis. ported. In contrast, occasional coexistence of INTRODUCTION pancreatitis with other systemic exocrinopathy has led to the concept of “a complex syndrome”,2 Since Sarles et al observed a case of particular “dry gland syndrome”,3 or “autoimmune exocrin- pancreatitis with hypergammaglobulinaemia,1 opathy.” The most commonly associated auto- occasional coexistence of pancreatitis with other immune disease is SjS.10–13 18 In addition, PSC, autoimmune diseases such as Sjögren’s syndrome ulcerative colitis, or systemic lupus erythemato- (SjS),2 primary sclerosing cholangitis (PSC),3 or sus was sometimes observed.17 18 However, it is primary biliary cirrhosis (PBC),3 has been re- still unclear whether or not the pathogenetic ported. These findings support the hypothesis mechanism of secondary (or syndromic) AIP with that an autoimmune mechanism may be involved other autoimmune diseases is different from pri- in the pathogenesis and pathophysiology in some mary AIP.13 17 It was noted that there is a patients with pancreatitis.4–14 Recently, similar possibility of developing systemic autoimmune cases without systemic autoimmune diseases diseases in patients previously diagnosed as hav- have been reported, which has led to the concept See end of article for ing primary AIP.13 17 authors’ affiliations of an autoimmune related pancreatitis,13 so called ....................... “autoimmune pancreatitis (AIP)”.5 Although it Correspondence to: has not yet been widely accepted as a new clinical ................................................. Dr K Okazaki, Department entity, the present article discusses the recent of Gastroenterology and concept of AIP. Abbreviations: ACA-II, anticarbonic anhydrase II Endoscopic Medicine, antibody; AIP, autoimmune related pancreatitis; ALF, Kyoto University Hospital, antilactoferrin antibody; ANA, antinuclear antibody; CA-II, Shogoin-Kawaracho, DEFINITION AND CONCEPT OF AIP carbonic anhydrase-II; ERCP, endoscopic retrograde Sakyo, Kyoto, 606-8507, Although the pathogenesis and pathophysiology Japan; okak@ of AIP are still unclear, clinical aspects have been cholangiopancreatography; IL, interleukin; LF, lactoferrin; kuhp.kyoto-u.ac.jp 4–14 PBC, primary biliary cirrhosis; PNPD, pancreatitis showing reported. The characteristic findings in most the narrowing appearance of the pancreatic duct; PSC, Accepted for publication cases of AIP can be summarised as follows (table primary sclerosing cholangitis; RF, rheumatoid factor; SjS, ....................... 1): Sjögren’s syndrome. www.gutjnl.com 2 Okazaki, Chiba Table 1 Characteristic findings of autoimmune pancreatitis • Increased levels of serum gammaglobulin or IgG • Presence of autoantibodies • Diffuse enlargement of the pancreas Gut: first published as 10.1136/gut.51.1.1 on 1 July 2002. Downloaded from • Diffusely irregular narrowing of the main pancreatic duct on ERCP images • Fibrotic changes with lymphocyte infiltration • No symptoms or only mild symptoms, usually without acute attacks of pancreatitis • Rare pancreatic calcification or pancreatic cysts • Occasional association with other autoimmune diseases • Effective steroid therapy • Association with diabetes mellitus often improved by steroid therapy ERCP, endoscopic retrograde cholangiopancreatography. EPIDEMIOLOGY OF AIP may be involved in inflammation. CD4+ T cells are further AIP is a rare disorder, although the exact prevalence is still subdivided into Th1 and Th2 cells based on profiles of cytokine unknown. More than 150 cases have been reported as AIP or production.12 Thl cells, which produce interleukin (IL)-2, PNPD in the Japanese literature.5–10 12 18 We identified 21 cases tumour necrosis factor α, and interferon γ, mediate cellular of AIP among our total of 451 patients with chronic immunity, macrophage activation, cytotoxicity, and help in B pancreatitis.13 Although our study did not show different mor- cell production of opsonising and complement fixing bidities between the sexes, males were usually predominant in antibodies.12 Japan.12 13 18 Mean age at diagnosis was more than 55 years.12 13 18 “Th1 cytokines may be essential in the induction and/or maintenance of AIP while Th2 cytokines may be “AIP is a rare disorder, although the exact prevalence involved in disease progression” is still unknown” In contrast, Th2 cells, which produce IL-4, 5, 6, and 10, pro- Diabetes mellitus was observed in about half of AIP patients mote humoral and allergic responses.12 In SjS24 and PSC,25 the ∼ (43 68%) and the majority showed type 2 diabetes major infiltrating cells in the tissue are CD4+HLA-DR+ Th1, 13 18 19 mellitus. Although the exact morbidity of primary and although CD8+ and B cells are also present. In some cases of secondary AIP is unclear, more than half of the cases were of AIP, CD4+ Th1 cells are predominant over Th2 type cells.12 12 13 18 the primary type. Therefore, similar to SjS,24 Th1 cytokines may be essential in the induction and/or maintenance of AIP while Th2 cytokines http://gut.bmj.com/ PATHOPHYSIOLOGY OF AIP may be involved in disease progression, especially local B cell Humoral immunity and target antigens activation. An animal model of AIP,using neonatally thymec- Occasional coexistence of pancreatitis with other autoimmune tomised BALB/c mice immunised with CA-II or LF and trans- diseases suggests that there may be common target antigens ferred nude mice, showed that CD4+ Th1 cells are mainly in the pancreas and other exocrine organs, such as the salivary involved in the early development of murine AIP.26 glands, biliary tract, and renal tubules. Several autoantibodies such as antinuclear antibody (ANA), antilactoferrin (LF) antibody (ALF), anticarbonic anhydrase II (CA-II) antibody ASSOCIATED DISEASES on September 26, 2021 by guest. Protected copyright. (ACA-II), and rheumatoid factor (RF) were frequently 12 13 Biliary ductal lesions detected in patients with AIP. CA-II and LF are distributed Patients with AIP often show narrowing of the common bile in the cells of several exocrine organs, including the pancreas, 12 duct, mainly in the intrapancreatic area, which may result in salivary glands, biliary duct, and distal renal tubules. The dilatation of the upper biliary tract. The sclerosing changes of high prevalence of these antibodies suggests that CA-II and LF the extrapancreatic bile duct, similar to PSC, are reported as may be candidates for the target antigens in AIP. However, it “lymphoplasmacytic sclerosing pancreatitis with was found that these autoantibodies are not necessarily 15 14 12 cholangitis”, “sclerosing pancreatocholangitis”, or an “in- specific for AIP. Although the majority of diabetic patients flammatory pseudotumour from sclerosing cholangitis”.1 In with associated
Load more

Recommended publications
  • Chronic Pancreatitis. 2
    Module "Fundamentals of diagnostics, treatment and prevention of major diseases of the digestive system" Practical training: "Chronic pancreatitis (CP)" Topicality The incidence of chronic pancreatitis is 4.8 new cases per 100 000 of population per year. Prevalence is 25 to 30 cases per 100 000 of population. Total number of patients with CP increased in the world by 2 times for the last 30 years. In Ukraine, the prevalence of diseases of the pancreas (CP) increased by 10.3%, and the incidence increased by 5.9%. True prevalence rate of CP is difficult to establish, because diagnosis is difficult, especially in initial stages. The average time of CP diagnosis ranges from 30 to 60 months depending on the etiology of the disease. Learning objectives: to teach students to recognize the main symptoms and syndromes of CP; to familiarize students with physical examination methods of CP; to familiarize students with study methods used for the diagnosis of CP, the determination of incretory and excretory pancreatic insufficiency, indications and contraindications for their use, methods of their execution, the diagnostic value of each of them; to teach students to interpret the results of conducted study; to teach students how to recognize and diagnose complications of CP; to teach students how to prescribe treatment for CP. What should a student know? Frequency of CP; Etiological factors of CP; Pathogenesis of CP; Main clinical syndromes of CP, CP classification; General and alarm symptoms of CP; Physical symptoms of CP; Methods of
    [Show full text]
  • Autoimmune Hepatitis
    Page 1 of 5 Autoimmune Hepatitis Autoimmune hepatitis is an uncommon cause of chronic hepatitis (persistent liver inflammation). The cause is not known. If left untreated, the inflammation causes cirrhosis (scarring of the liver). However, with treatment, the outlook for people with this condition is very good. Treatment is usually with steroids and other medicines which suppress inflammation. What does the liver do? The liver is in the upper right part of the abdomen. It has many functions which include: Storing glycogen (fuel for the body) which is made from sugars. When required, glycogen is broken down into glucose which is released into the bloodstream. Helping to process fats and proteins from digested food. Making proteins that are essential for blood to clot (clotting factors). Processing many medicines which you may take. Helping to remove or process alcohol, poisons and toxins from the body. Making bile which passes from the liver to the gut down the bile duct. Bile breaks down the fats in food so that they can be absorbed from the bowel. What is autoimmune hepatitis? Hepatitis means inflammation of the liver. There are many causes of hepatitis. For example, alcohol excess and infections with various viruses are the common causes of hepatitis. Autoimmune hepatitis is an uncommon cause of chronic hepatitis. Chronic means that the inflammation is persistent or long-term. The chronic inflammation gradually damages the liver cells, which can result in serious problems. What causes autoimmune hepatitis? Page 2 of 5 The cause is not clear. It is thought to be an autoimmune disease. Our immune system normally defends us against infection from bacteria, viruses and other germs.
    [Show full text]
  • EASL Clinical Practice Guidelines: Autoimmune Hepatitisq
    Clinical Practice Guidelines EASL Clinical Practice Guidelines: Autoimmune hepatitisq ⇑ European Association for the Study of the Liver striking progress, and now patients in specialised centres have an Introduction excellent prognosis, both in respect to survival and to quality of life. Autoimmune hepatitis (AIH) was the first liver disease for which The aim of the present Clinical Practice Guideline (CPG) is to an effective therapeutic intervention, corticosteroid treatment, provide guidance to hepatologists and general physicians in the was convincingly demonstrated in controlled clinical trials. diagnosis and treatment of AIH in order to improve care for However, 50 years later AIH still remains a major diagnostic affected patients. In view of the limited data from large con- and therapeutic challenge. There are two major reasons for this trolled studies and trials, many recommendations are based on apparent contradiction: Firstly, AIH is a relatively rare disease. expert consensus. This is to some extent a limitation of this Secondly, AIH is a very heterogeneous disease. EASL-CPG, but at the same time it is its special strength: consen- Like other rare diseases, clinical studies are hampered by the sus in this guideline is based on intensive discussions of experts limited number of patients that can be included in trials. Possibly from large treatment centres. The core consensus group has and more importantly, the interest of the pharmaceutical indus- experience of over one thousand AIH patients managed person- try to develop effective specific therapies for rare diseases is lim- ally, and the recommendations have been reviewed by both the ited due to the very restricted market for such products.
    [Show full text]
  • AASLD PRACTICE GUIDELINES Diagnosis and Management of Autoimmune Hepatitis
    AASLD PRACTICE GUIDELINES Diagnosis and Management of Autoimmune Hepatitis Michael P. Manns,1 Albert J. Czaja,2 James D. Gorham,3 Edward L. Krawitt,4 Giorgina Mieli-Vergani,5 Diego Vergani,6 and John M. Vierling7 This guideline has been approved by the American ment on Guidelines;3 and (4) the experience of the Association for the Study of Liver Diseases (AASLD) authors in the specified topic. and represents the position of the Association. These recommendations, intended for use by physi- cians, suggest preferred approaches to the diagnostic, 1. Preamble therapeutic and preventive aspects of care. They are intended to be flexible, in contrast to standards of Clinical practice guidelines are defined as ‘‘systemati- care, which are inflexible policies to be followed in ev- cally developed statements to assist practitioner and ery case. Specific recommendations are based on rele- patient decisions about appropriate heath care for spe- vant published information. To more fully characterize 1 cific clinical circumstances.’’ These guidelines on the quality of evidence supporting the recommenda- autoimmune hepatitis provide a data-supported tions, the Practice Guidelines Committee of the approach to the diagnosis and management of this dis- AASLD requires a class (reflecting benefit versus risk) ease. They are based on the following: (1) formal and level (assessing strength or certainty) of evidence review and analysis of the recently-published world lit- to be assigned and reported with each recommenda- erature on the topic [Medline search]; (2) American tion.4 The grading system applied to the recommenda- College of Physicians Manual for Assessing Health tions has been adapted from the American College of 2 Practices and Designing Practice Guidelines; (3) Cardiology and the American Heart Association Prac- guideline policies, including the AASLD Policy on the tice Guidelines, and it is given below (Table 1).
    [Show full text]
  • Pancreatic Disorders in Inflammatory Bowel Disease
    Submit a Manuscript: http://www.wjgnet.com/esps/ World J Gastrointest Pathophysiol 2016 August 15; 7(3): 276-282 Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx ISSN 2150-5330 (online) DOI: 10.4291/wjgp.v7.i3.276 © 2016 Baishideng Publishing Group Inc. All rights reserved. MINIREVIEWS Pancreatic disorders in inflammatory bowel disease Filippo Antonini, Raffaele Pezzilli, Lucia Angelelli, Giampiero Macarri Filippo Antonini, Giampiero Macarri, Department of Gastro- acute pancreatitis or chronic pancreatitis has been rec­ enterology, A.Murri Hospital, Polytechnic University of Marche, orded in patients with inflammatory bowel disease (IBD) 63900 Fermo, Italy compared to the general population. Although most of the pancreatitis in patients with IBD seem to be related to Raffaele Pezzilli, Department of Digestive Diseases and Internal biliary lithiasis or drug induced, in some cases pancreatitis Medicine, Sant’Orsola-Malpighi Hospital, 40138 Bologna, Italy were defined as idiopathic, suggesting a direct pancreatic Lucia Angelelli, Medical Oncology, Mazzoni Hospital, 63100 damage in IBD. Pancreatitis and IBD may have similar Ascoli Piceno, Italy presentation therefore a pancreatic disease could not be recognized in patients with Crohn’s disease and ulcerative Author contributions: Antonini F designed the research; Antonini colitis. This review will discuss the most common F and Pezzilli R did the data collection and analyzed the data; pancreatic diseases seen in patients with IBD. Antonini F, Pezzilli R and Angelelli L wrote the paper; Macarri G revised the paper and granted the final approval. Key words: Pancreas; Pancreatitis; Extraintestinal mani­ festations; Exocrine pancreatic insufficiency; Ulcerative Conflict­of­interest statement: The authors declare no conflict colitis; Crohn’s disease; Inflammatory bowel disease of interest.
    [Show full text]
  • Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease
    pathogens Article Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease Patients from Southern Italy: A Case-Control Study Giuseppe Losurdo 1,2 , Andrea Iannone 1, Antonella Contaldo 1, Michele Barone 1 , Enzo Ierardi 1 , Alfredo Di Leo 1,* and Mariabeatrice Principi 1 1 Section of Gastroenterology, Department of Emergency and Organ Transplantation, University “Aldo Moro” of Bari, 70124 Bari, Italy; [email protected] (G.L.); [email protected] (A.I.); [email protected] (A.C.); [email protected] (M.B.); [email protected] (E.I.); [email protected] (M.P.) 2 Ph.D. Course in Organs and Tissues Transplantation and Cellular Therapies, Department of Emergency and Organ Transplantation, University “Aldo Moro” of Bari, 70124 Bari, Italy * Correspondence: [email protected]; Tel.: +39-080-559-2925 Received: 14 September 2020; Accepted: 21 October 2020; Published: 23 October 2020 Abstract: We performed an epidemiologic study to assess the prevalence of chronic viral hepatitis in inflammatory bowel disease (IBD) and to detect their possible relationships. Methods: It was a single centre cohort cross-sectional study, during October 2016 and October 2017. Consecutive IBD adult patients and a control group of non-IBD subjects were recruited. All patients underwent laboratory investigations to detect chronic hepatitis B (HBV) and C (HCV) infection. Parameters of liver function, elastography and IBD features were collected. Univariate analysis was performed by Student’s t or chi-square test. Multivariate analysis was performed by binomial logistic regression and odds ratios (ORs) were calculated. We enrolled 807 IBD patients and 189 controls. Thirty-five (4.3%) had chronic viral hepatitis: 28 HCV (3.4%, versus 5.3% in controls, p = 0.24) and 7 HBV (0.9% versus 0.5% in controls, p = 0.64).
    [Show full text]
  • Primary Biliary Cholangitis: a Brief Overview Justin S
    REVIEW Primary Biliary Cholangitis: A Brief Overview Justin S. Louie,* Sirisha Grandhe,* Karen Matsukuma,† and Christopher L. Bowlus* Primary biliary cholangitis (PBC), previously referred to supported by the higher concordance of PBC in monozy- as primary biliary cirrhosis, is the most common chronic gotic compared with dizygotic twins.4 In addition, certain cholestatic autoimmune disease affecting adults in the human leukocyte antigen haplotypes have been associ- United States.1 It is characterized by a hallmark serologic ated with PBC, as well as variants at loci along the inter- signature, antimitochondrial antibody (AMA), and specific leukin-12 (IL-12) immunoregulatory pathway (IL-12A and bile duct pathology with progressive intrahepatic duct de- IL-12RB2 loci).5 struction leading to cholestasis. PBC is potentially fatal and can have both intrahepatic and extrahepatic complications. PATHOGENESIS EPIDEMIOLOGY The primary disease mechanism in PBC is thought to be T cell lymphocyte–mediated injury against intralobu- PBC affects all races and ethnicities; however, it is best lar biliary epithelial cells. This causes progressive destruc- studied in the Caucasian population. The condition pre- tion and eventual disappearance of the intralobular bile dominantly affects women older than 40 years, with a ducts. Molecular mimicry has been proposed as the ini- female/male ratio of 9:1.2 Although the incidence of PBC tiating event in the loss of tolerance primarily to mito- appears to be stable, the overall prevalence of the disease chondrial pyruvate dehydrogenase complex, E2, during is increasing.3 An individual’s genetic susceptibility, epige- which exogenous antigens evoke an immune response netic factors, and certain environmental triggers seem to that recognizes an endogenous (self) antigen inciting an play important roles.
    [Show full text]
  • ESPEN Guideline on Clinical Nutrition in Acute and Chronic Pancreatitis
    Clinical Nutrition 39 (2020) 612e631 Contents lists available at ScienceDirect Clinical Nutrition journal homepage: http://www.elsevier.com/locate/clnu ESPEN Guideline ESPEN guideline on clinical nutrition in acute and chronic pancreatitis * Marianna Arvanitakis a, , Johann Ockenga b, Mihailo Bezmarevic c, Luca Gianotti d, , Zeljko Krznaric e, Dileep N. Lobo f g, Christian Loser€ h, Christian Madl i, Remy Meier j, Mary Phillips k, Henrik Højgaard Rasmussen l, Jeanin E. Van Hooft m, Stephan C. Bischoff n a Department of Gastroenterology, Erasme University Hospital ULB, Brussels, Belgium b Department of Gastroenterology, Endocrinology and Clinical Nutrition, Klinikum Bremen Mitte, Bremen, Germany c Department of Hepatobiliary and Pancreatic Surgery, Clinic for General Surgery, Military Medical Academy, University of Defense, Belgrade, Serbia d School of Medicine and Surgery, University of Milano-Bicocca and Department of Surgery, San Gerardo Hospital, Monza, Italy e Department of Gastroenterology, Hepatology and Nutrition, Clinical Hospital Centre & School of Medicine, Zagreb, Croatia f Gastrointestinal Surgery, Nottingham Digestive Diseases Centre, National Institute for Health Research. (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK g MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK h Medical Clinic, DRK-Kliniken
    [Show full text]
  • Clinical Biliary Tract and Pancreatic Disease
    Clinical Upper Gastrointestinal Disorders in Urgent Care, Part 2: Biliary Tract and Pancreatic Disease Urgent message: Upper abdominal pain is a common presentation in urgent care practice. Narrowing the differential diagnosis is sometimes difficult. Understanding the pathophysiology of each disease is the key to making the correct diagnosis and providing the proper treatment. TRACEY Q. DAVIDOFF, MD art 1 of this series focused on disorders of the stom- Pach—gastritis and peptic ulcer disease—on the left side of the upper abdomen. This article focuses on the right side and center of the upper abdomen: biliary tract dis- ease and pancreatitis (Figure 1). Because these diseases are regularly encountered in the urgent care center, the urgent care provider must have a thorough understand- ing of them. Biliary Tract Disease The gallbladder’s main function is to concentrate bile by the absorption of water and sodium. Fasting retains and concentrates bile, and it is secreted into the duodenum by eating. Impaired gallbladder contraction is seen in pregnancy, obesity, rapid weight loss, diabetes mellitus, and patients receiving total parenteral nutrition (TPN). About 10% to 15% of residents of developed nations will form gallstones in their lifetime.1 In the United States, approximately 6% of men and 9% of women 2 have gallstones. Stones form when there is an imbal- ©Phototake.com ance in the chemical constituents of bile, resulting in precipitation of one or more of the components. It is unclear why this occurs in some patients and not others, Tracey Q. Davidoff, MD, is an urgent care physician at Accelcare Medical Urgent Care in Rochester, New York, is on the Board of Directors of the although risk factors do exist.
    [Show full text]
  • Abdominal Pain
    10 Abdominal Pain Adrian Miranda Acute abdominal pain is usually a self-limiting, benign condition that irritation, and lateralizes to one of four quadrants. Because of the is commonly caused by gastroenteritis, constipation, or a viral illness. relative localization of the noxious stimulation to the underlying The challenge is to identify children who require immediate evaluation peritoneum and the more anatomically specific and unilateral inner- for potentially life-threatening conditions. Chronic abdominal pain is vation (peripheral-nonautonomic nerves) of the peritoneum, it is also a common complaint in pediatric practices, as it comprises 2-4% usually easier to identify the precise anatomic location that is produc- of pediatric visits. At least 20% of children seek attention for chronic ing parietal pain (Fig. 10.2). abdominal pain by the age of 15 years. Up to 28% of children complain of abdominal pain at least once per week and only 2% seek medical ACUTE ABDOMINAL PAIN attention. The primary care physician, pediatrician, emergency physi- cian, and surgeon must be able to distinguish serious and potentially The clinician evaluating the child with abdominal pain of acute onset life-threatening diseases from more benign problems (Table 10.1). must decide quickly whether the child has a “surgical abdomen” (a Abdominal pain may be a single acute event (Tables 10.2 and 10.3), a serious medical problem necessitating treatment and admission to the recurring acute problem (as in abdominal migraine), or a chronic hospital) or a process that can be managed on an outpatient basis. problem (Table 10.4). The differential diagnosis is lengthy, differs from Even though surgical diagnoses are fewer than 10% of all causes of that in adults, and varies by age group.
    [Show full text]
  • Chronic Pancreatitis
    CHRONIC PANCREATITIS Chronic pancreatitis is an inflammatory pancreas disease with the development of parenchyma sclerosis, duct damage and changes in exocrine and endocrine function. The causes of chronic pancreatitis Alcohol; Diseases of the stomach, duodenum, gallbladder and biliary tract. With hypertension in the bile ducts of bile reflux into the ducts of the pancreas. Infection. Transition of infection from the bile duct to the pancreas, By the vessels of the lymphatic system, Medicinal. Long -term administration of sulfonamides, antibiotics, glucocorticosteroids, estrogens, immunosuppressors, diuretics and NSAIDs. Autoimmune disorders. Congenital disorders of the pancreas. Heredity; In the progression of chronic pancreatitis are playing important pathological changes in other organs of the digestive system. The main symptoms of an exacerbation of chronic pancreatitis: Attacks of pain in the epigastric region associated or not with a meal. Pain radiating to the back, neck, left shoulder; Inflammation of the head - the pain in the right upper quadrant, body - pain in the epigastric proper region, tail - a pain in the left upper quadrant. Pain does not subside after vomiting. The pain increases after hot-water bottle. Dyspeptic disorders, including flatulence, Malabsorption syndrome: Diarrhea (50%). Feces unformed, (steatorrhea, amylorea, creatorrhea). Weight loss. On examination, patients. Signs of hypovitaminosis (dry skin, brittle hair, nails, etc.), Hemorrhagic syndrome - a symptom of Gray-Turner (subcutaneous hemorrhage and cyanosis on the lateral surfaces of the abdomen or around the navel) Painful points in the pathology of the pancreas Point choledocho – pankreatic. Kacha point. The point between the outer and middle third of the left costal arch. The point of the left phrenic nerve.
    [Show full text]
  • Fatty Liver Disease a Practical Guide for Gps David Iser Marno Ryan
    The right upper quadrant Fatty liver disease A practical guide for GPs David Iser Marno Ryan Background First described in 1980,1 non-alcoholic fatty liver disease Non-alcoholic fatty liver disease (NAFLD), encompassing both (NAFLD) is now the most common cause of liver disease in simple steatosis and non-alcoholic steato-hepatitis (NASH), is the industrialised countries.2 Non-alcoholic fatty liver disease most common cause of liver disease in Australia. Non-alcoholic includes both non-alcoholic steato-hepatitis (NASH), involving fatty liver disease needs to be considered in the context of the lobular inflammation and fibrosis, and simple steatosis (non- metabolic syndrome, as cardiovascular disease will account for NASH). This distinction is important, as simple steatosis much of the mortality associated with NAFLD. is unlikely to lead to liver related complications, whereas Objective NASH may lead to increased fibrosis and cirrhosis, and its To provide an approach to the identification of NAFLD in general complications (Figure 1). The difficulty lies in trying to decide practice, the distinction between simple steatosis and NASH, whether raised liver functions tests (LFTs) are due to simple and the management of these two conditions. steatosis, NASH without fibrosis, NASH with severe fibrosis Discussion or cirrhosis, or another cause of hepatitis altogether. Non-alcoholic steato-hepatitis is more common in the presence of diabetes, obesity, older age and increased inflammation, and is Epidemiology more likely to progress to cirrhosis. Cirrhosis may be complicated The prevalence of NAFLD is estimated to be approximately 30% of by hepatocellular carcinoma or liver failure. Hepatocellular adults in developed countries such as Australia and the United States, carcinoma has also been described in NASH without cirrhosis.
    [Show full text]